A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC

Trial Profile

A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top